Evidence map›Paper›PMID 29058701›Full record

ArticleBone marrow transplantation2018

NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.

B Jeker, U Novak, B Mansouri Taleghani, G M Baerlocher, K Seipel, B U Mueller, M Bigler, D Betticher, J-M Luethi, S Farese and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

B JekerDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
U NovakDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
B Mansouri TaleghaniDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
G M BaerlocherDepartment of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
K SeipelDepartment of Clinical Research, University of Bern, Bern, Switzerland.
B U MuellerDepartment of Clinical Research, University of Bern, Bern, Switzerland.
M BiglerSAKK Coordinating Centre, Bern, Switzerland.
D BetticherDepartment of Oncology, Kantonsspital, Fribourg, Switzerland.
J-M LuethiDepartment of Oncology, Regionalspital, Thun, Switzerland.
S FareseDepartment of Oncology, Kantonsspital, Solothurn, Switzerland.
A RueferDepartment of Hematology, Kantonsspital, Lucerne, Switzerland.
T PabstDepartment of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
University of Bern · CHUniversity Hospital of Bern · CHHFR Freiburg Kantonsspital · CHLuzerner Kantonsspital · CHRegionalspital Emmental · CHSolothurner Spitäler · CHSwiss Group For Clinical Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy with G-CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing patients. Preclinical studies suggested that the nonsteroidal anti-inflammatory drug meloxicam enhances the mobilization of CD34

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalFemaleHematopoietic Stem Cell MobilizationHumansMaleMeloxicamMiddle AgedMultiple MyelomaPeripheral Blood Stem Cell TransplantationAnti-Inflammatory Agents, Non-SteroidalMeloxicam

Identifiers

PMID29058701
OpenAlexW2765580181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.